SAXENDA (liraglutide) The first GLP-1 medication, Saxenda (liraglutide) was launched in 2010 by the same Danish pharmaceutical company Novo Nordisk which manufactures other diabetes medicines including insulin and Ozempic
Spending rose modestly to $890 million in 2023, but it is being phased out by patients in favor of weekly options Ama-Assn
The Cochrane collaborations tool for assessing risk of bias in randomised trials
Stress triggers stress hormones that make your body want to hold onto fat, and poor quality or insufficient sleep puts your body into a state of chronic stress
Its found in large amounts in the heart, brain, eyes, and skeletal muscles, and its antioxidant effects protect against mitochondrial disorders and defects that occur with aging, various mitochondrial diseases, metabolic syndrome, cancers, cardiovascular diseases and neurological disorders
Fleur's concept addresses the limitations of current therapies through a biomimetic strategy that leverages the body's natural GLP-1 production mechanisms: Utilize a probiotic oral delivery system to populate the gut microbiome long-term with natural (short-lasting) GLP-1 producing bacteria
